TW201100088A - Extraction methods and compositions to improve hyperlipidemia, hyperglycermia and fatty liver - Google Patents

Extraction methods and compositions to improve hyperlipidemia, hyperglycermia and fatty liver Download PDF

Info

Publication number
TW201100088A
TW201100088A TW98121165A TW98121165A TW201100088A TW 201100088 A TW201100088 A TW 201100088A TW 98121165 A TW98121165 A TW 98121165A TW 98121165 A TW98121165 A TW 98121165A TW 201100088 A TW201100088 A TW 201100088A
Authority
TW
Taiwan
Prior art keywords
powder
licorice
bitter gourd
fatty liver
extract
Prior art date
Application number
TW98121165A
Other languages
Chinese (zh)
Other versions
TWI387460B (en
Inventor
Tsung-Chi Tsai
Hsien-Tung Yen
Chia-Chun Lin
Original Assignee
Uni President Entpr Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uni President Entpr Corp filed Critical Uni President Entpr Corp
Priority to TW98121165A priority Critical patent/TWI387460B/en
Publication of TW201100088A publication Critical patent/TW201100088A/en
Application granted granted Critical
Publication of TWI387460B publication Critical patent/TWI387460B/en

Links

Abstract

By using PPAR α and PPAR γ transactivation assay, we successfully identified the extraction methods and composition of bitter gourd, licorice, soybean protein, and chlorella could exert the highest activation ability of PPAR α and PPAR γ. We further demonstrated the efficacy in animal models and human models to ameliorate hyperlipidemia, hyperglycermia and fatty liver.

Description

201100088 六、發明說明: 【發明所屬之技術領域】 一種保健食品之配方組合及其各素材之抽出方法 【先前技術】 在已開發國家中’脂質與賴代謝不佳,容易產生代謝症候群的症狀, 如糖尿病、高血壓、高血脂、動脈硬化、高三酸甘油酯等疾病,然近 年來的研究發現’這些疾,觸與峨射的受體—ppARs(脂小體活化 增生受體)有關。目前有許多科學家都在找尋可以活化ppARs的活化子 Ο 當成代謝症候群的藥物,例如:thiazolidiiiediones(TZD)(騰島素增 敏劑)為活化PPARr而具有降灰糖的效果,而fibrates (苯氧芳雙類) 為活化PPARa且有降血脂的效果,但由於以上皆屬於藥物,同時呈有 副作用,不適合長期食用。 〃 近年來,有少量文獻由-些古方常用的降血糖素材,驗證是否是經由 活化PPARr而達到降血糖的效果,並触可以由這些天然的成分去找 尋更,可以活化PPAR的化合物,以便進行藥物的開發。目前文獻的素 材都是以單方為主,例如:啤酒花抽出物可以同時活化ppARα及^、苦 瓜抽出物可以同時活化ΡΡ勤及r、甘草抽出物活化ρρ斷…等,但 這些有效成分往往需要經過特殊的有機溶劑去萃取,才可以獲得有效 赋分。但以食品的觀念,經過有機溶鮮取並不適合應驗食品。 所以本專利就是利用特殊酒精和/或水的抽取及配合最佳之各素材之 組cr比例’以獲知最有效(血脂、血糖、脂肪肝)的食品複方配方。 201100088 【發明内容】 目前降血糖及降血脂的藥物有許多都是經由活化PPARa及r所 開發完成,所以功效及機制原理已經經過許多專家學者確認,但是這 類的藥tm彳主在gj為化學合成的化合物,而使—些受試者產生肝 臟或腎臟的毒性’因而使身體的GOT (麵氣基酸草醋酸轉氨基酵素) ,GPT (楚氨基酸焦葡萄轉氨基酵素)值變高,所以本專利的想法就 疋利用醫藥界找尋活化PPAR活化物的方法,對於目前人類常吃的素 材以食品可用的溶劑進行篩選,找出具有活化pp版及r天然化合 物或複方組合,以造福更多的人。 〇 本創意疋一種具有調降血糖血脂以及改善脂肪肝的多效複方食 品組合及其純方法,其概在於添減例為苦瓜 20〜40%、甘草 1%〜10%、綠藻15%〜30%、大豆蛋白粉2(M〇%。而其各素材抽出物 之抽取方法分別如下: 餘的HL苦瓜先_汁機_取苦瓜汁液,剩 ΐίίίί ί.200 ml気以上的酒精浸泡6至8個小時後, ssm ό把苦瓜汁液和酒精抽提物混合進行冷康乾燥’ 乙 Ο 丙 草物:100克甘草經過粉碎後,加入500〜1〇_體積 Ϊ純ϋ100,振盪室溫浸泡10小時以上,除去甘草殘法積 讀冷絲燥成粉末,此"粉末再以5(Η_甲醇浸 泡20i、i以上’將醇溶的部份再乾燥成粉末而成。 克5麟藻粉,以500〜1000ml 100°c彿水進行抽 ?鐘將此水溶液以l〇mm-5咖f·以分子篩過濾、,除去殘 >一水溶液部分進行濃縮與乾燥喷粉而成。 ’、 Π : 100克脫油的豆粕,以300〜5_的水,加入 ΐ^ f f 丨素^〇_idase (E.C. 3.4. 24. 28 ),於 10000 DaTtiTT^ 5 將上述的配方組成進行動物與人體試驗的使用,證實有調降血 脂、血糖與改善脂肪肝的功效,且以上製程的複方組合效果好具有 好的水中擴散性’可以顧其他複方食品組合,包括膠囊錠劑、穀 201100088 粉、飲料、口服液產品的開發。 【實施方式】 利用所建立轉染PPAR 0:及PPAR r之細胞的方法 (transactivation assay system)(轉染細胞活化系統)——於活化 PPAR啟動子基因的後方’接入冷光的基因,再把此基因送入表現的 肝臟細胞,接著使用素材去刺激細胞,當素材具有活化PPAR的能 力,即可以由冷光儀測出冷光的強弱變化,以此決定素材活化PPAR α及PPAR«r的效果,也可以應用此技術決定製程及搭配複方組合。 Ο201100088 VI. Description of the invention: [Technical field of invention] A formula combination of a health food and a method for extracting each material [Prior Art] In a developed country, 'lipid and lysate metabolism is poor, and symptoms of metabolic syndrome are easily generated. Such as diabetes, hypertension, hyperlipidemia, arteriosclerosis, high triglycerides and other diseases, but recent studies have found that 'these diseases, contact with the sputum receptor - ppARs (liposome activated proliferative receptors). Many scientists are currently looking for activators that can activate ppARs as drugs for metabolic syndrome, such as: thiazolidiiiediones (TZD) (Tengdao sensitizer) has the effect of reducing ash sugar by activating PPARr, while fibrates The two types are activated PPARa and have the effect of lowering blood fat, but since all of the above are drugs, they have side effects and are not suitable for long-term consumption. 〃 In recent years, there has been a small amount of literature on the hypoglycemic materials commonly used in ancient times to verify whether the effect of lowering blood glucose is achieved by activating PPARr, and the natural ingredients can be found to activate PPAR compounds for the purpose of Drug development. At present, the materials in the literature are mainly unilateral. For example, hop extracts can simultaneously activate ppARα and ^, bitter gourd extract can simultaneously activate retort and r, licorice extract activation ρρ break, etc., but these active ingredients often need to go through Special organic solvents are extracted to obtain effective scores. However, in the concept of food, it is not suitable for the food to be tested after organic dissolution. Therefore, this patent is to use the special alcohol and / or water extraction and the best ratio of each group of materials to determine the most effective (lipid, blood sugar, fatty liver) food compound formula. 201100088 【Abstract】 At present, many drugs for lowering blood sugar and lowering blood fat are developed through activation of PPARa and r. Therefore, the principle of efficacy and mechanism has been confirmed by many experts and scholars, but this kind of medicine is mainly used in gj. Synthetic compounds, which cause some subjects to produce liver or kidney toxicity', thus making the body's GOT (gumaceous acid acetic acid transaminase), GPT (Chu amino acid pyropolysaccharide) higher, so The idea of this patent is to use the medical community to find a way to activate PPAR activators. For the materials that humans often eat, the foods can be screened for foods to find the activated pp plate and r natural compounds or compound combinations for the benefit of more. People. 〇本创意 疋 A multi-effect combination of foods with blood sugar lowering and improved fatty liver and its pure method, which are added and subtracted as bitter melon 20~40%, licorice 1%~10%, green algae 15%~ 30%, soy protein powder 2 (M〇%. The extraction method of each material is as follows: the remaining HL bitter melon first _ juice machine _ take bitter melon juice, left ΐ ί ί ί ί 200 200 200 200 200 200 200 200 200 After 8 hours, ssm 混合 mix the bitter gourd juice and alcohol extract for cold drying ' 乙 Ο 丙 丙: 100 grams of licorice after crushing, add 500~1 〇 _ volume Ϊ pure ϋ 100, shake at room temperature 10 After more than an hour, remove the licorice residue and read the cold-dried powder into a powder. This powder is then dried into a powder by soaking the alcohol-soluble portion with 5 (Η_methanol soaked for 20i, i or more). , pumping 500~1000ml of 100°c water for the pumping time to filter the aqueous solution with l分子mm-5 coffee f·molecular sieve, removing the residual > an aqueous solution portion for concentration and drying and dusting. ', Π : 100 grams of degreased soybean meal, with 300~5_ of water, add ΐ^ ff 丨 〇 ^〇_idase (EC 3.4. 24. 28), at 10000 DaTtiTT^ 5 The above formula was used for animal and human trials, which confirmed the effects of lowering blood fat, blood sugar and improving fatty liver, and the combination of the above processes has good effect and good water diffusion. The 'ability' can be considered for other compound food combinations, including the development of capsule lozenges, Gu 201100088 powder, beverages, oral liquid products. [Embodiment] The method of transfecting PPAR 0: and PPAR r cells (transactivation assay system) was established. (transfected cell activation system) - accessing the luminescent signal behind the activated PPAR promoter gene, then sending the gene to the expressed liver cells, and then using the material to stimulate the cells, when the material has the ability to activate PPAR, That is, the intensity of the cold light can be measured by the luminometer to determine the effect of the material activation PPAR α and PPAR «r, and the technique can also be used to determine the process and the combination of the combinations.

經過對許多食品素材進行篩選,發現以下四個素材有很好的活 性’並進行不同萃取方式’找出以下的專利製程,有最好的活化ppAR 效果,製造的方法如下: 甲、苦瓜抽出物:1〇〇克新鮮苦瓜先以榨汁機榨取苦瓜汁液,餘 殘的渣再以100〜200 ml 90%以上的酒精浸泡6至8個小時後,過 濾去除殘渣,把苦瓜汁液和酒精抽提物混合進行冷凍乾燥,製 成粉末而成。 乙 丙 .甘草抽出物:1〇〇克甘草經過粉碎後,加入5〇〇〜i〇〇〇mi體積 的純水以6(M〇〇rpin振盪室溫浸泡1〇小時以上,除去甘草殘渣後 將上π液冷;東乾燥成粉末,此一粉末再以50〜100ml甲醇浸泡20 小時以上,將醇溶的部份再乾燥成粉末而成。 ' 綠藻:100克破壁綠藻粉,以50(M000 mllOOt:沸水進行抽 取60〜180分鐘,將此水溶液以刪_5麵以分子篩過濾,除去殘 渣部份,水溶液部分進行濃縮與乾燥喷粉而成。 ” 丁、 大豆蛋白粉:100克脫油的豆粕,以300〜500ml的水,加入 0. 3%〜3%蛋白分解酵素end〇peptidase (E. C. 3. 4. 24· 28 ),於 45-50度下作用6-8小時,經過過濾,取濾液,以分子篩過濾取 10000 Dalton以下的成分。 1 接著進行複方的組合及搭配,利用以上四個專利製程所抽取的素 材,找出最佳的誘發劑量的活性,此外也進行素材排列組合,實驗 結果發現這四種素材搭配在一起後,經過PPARa及ppAR τ之細胞株 篩選方法確定效果比單方或是其他配方任意組合(總濃度相同下比 較)有更好的活化PPARa及PPARγ的能力(如下圖一及圖二)。圖一: 表示活化PPARa的倍數,圖二表示活化PPARr的倍數。而控制組為 201100088 只用水去刺激細胞的結果’定其活化倍數為100% (1倍),而甘草、 苦瓜、綠藻、大丑其對ΡΡΑΚα的最高活化程度只有1.5、L4、2 3、 2.1倍,當四個成份組合一起時,ppARa的最高活化程度可以高達 5.3倍’而四個單方對ppARr的最高活化程度分別為2.9、1.3、1.8、 1.9倍’當四個成份組合一起時,對ppARr^的最高活化程度高達5 〇 倍,以上結果証實此複方組合具有可加成活化ppARa和丫的效果, 優於單方的組合,有其進步性。 I (倍數办 水(控制組> 甘草*:- 細齡 大豆 稱!jie方3 !活化 PPARa*, Uv 1.4^ i 2.3^ 2丄, 5.3^ 丨丽 piSi:T^ 1^ .......-................ u,iik 1,9^ 5.0^ 〇 〇After screening many food materials, the following four materials were found to have good activity 'and different extraction methods' to find the following patented processes, which have the best activation ppAR effect, and the manufacturing methods are as follows: A, bitter gourd extract :1 新鲜 新鲜 fresh bitter gourd first extract the bitter gourd juice with juicer, and the remaining slag is soaked in 100~200 ml 90% alcohol for 6-8 hours, filter to remove the residue, extract bitter gourd juice and alcohol The mixture was lyophilized and made into a powder. Ethyl propylene. Licorice extract: 1 gram of licorice after pulverization, add 5 〇〇 ~ i 〇〇〇 mi volume of pure water to 6 (M 〇〇rpin shaking at room temperature for more than 1 hr, after removing licorice residue The upper π liquid is cooled; the east is dried into a powder, and the powder is further immersed in 50-100 ml of methanol for more than 20 hours, and the alcohol-soluble portion is further dried into a powder. ' Chlorella: 100 g of broken green algae powder, 50 (M000 mllOOt: boiling water for 60 to 180 minutes, the aqueous solution is filtered by molecular sieves to remove the residue, and the aqueous solution is partially concentrated and dried to be dusted. " Ding, soy protein powder: 100克油油豆粕, with 300~500ml of water, adding 0.3%~3% proteolytic enzyme end〇peptidase (EC 3. 4. 24· 28 ), acting at 45-50 degrees for 6-8 hours, After filtration, the filtrate is taken, and the components below 10000 Dalton are filtered by molecular sieve. 1 Then, the combination and combination of the compounds are used, and the materials extracted by the above four patent processes are used to find the best dose-inducing activity, and the material is also used. Arrange and combine, the experimental results found that these four materials When combined, the PPARa and ppAR τ cell line screening methods have better ability to activate PPARa and PPARγ than any combination of unilateral or other formulations (compared to the same total concentration) (see Figure 1 and Figure 2 below). Figure 1: Represents the multiple of activated PPARa, Figure 2 shows the multiple of activated PPARr, while the control group is 201100088. The result of using only water to stimulate cells is '100% (1 fold), while licorice, bitter melon, green algae The maximum activation degree of ΡΡΑΚα is only 1.5, L4, 2 3, 2.1 times. When the four components are combined, the maximum activation degree of ppARa can be as high as 5.3 times' and the maximum activation degree of four unilateral pairs of ppARr respectively 2.9, 1.3, 1.8, 1.9 times' When the four components are combined, the maximum activation degree of ppARr^ is up to 5 times. The above results confirm that the compound combination has the effect of adding ppARa and hydrazine, which is superior to unilateral. The combination has its progressiveness. I (multiple water (control group > licorice *:- fine soy called! jie side 3! Activate PPARa*, Uv 1.4^ i 2.3^ 2丄, 5.3^ 丨 piSi: T^ 1^ . ......-................ u,iik 1,9^ 5.0^ 〇 〇

Control ^ 100% 200% 300% <100% 500% m / riuControl ^ 100% 200% 300% <100% 500% m / riu

Η 184% IHiim184 184% IHiim

Control 0% 100% 200¾ 300% 400% 500¾ 600?ό FUf / RUi 圖 圖一 將上述的配方組合進一步進行血脂、血糖與脂肪肝的體内試驗, 以進一步證實其功效 201100088 _血脂血糖動物實驗:以成大動物中心所購買的C57BL/6品系老 鼠,經過高脂肪飼料的誘發,使老鼠產生高血糖及高血脂的症 狀,經過我們設計的配方餵食老鼠,可以發現老鼠經過3個星 期餵食後,具有降血糖(14. 6 %)及三酸甘油酯(21.8 %)的 效果,而在第六個星期可以看到降膽固醇(12.4 %)的效果。 _血脂血糖人體體驗:在血糖體驗者部份,經過一個月的服用, 血糖平均值由99.1 mg/dl降至94. 3mg/dl (降幅5 %)。而在血 脂體驗者的部分,經過一個月的測試,所有體驗者的膽固醇平 均值由233 mg/dl降至207 mg/dl(降幅11.1%);而三酸甘油酯 的平均值由221mg/dl降至I62mg/dl(降幅26. 7%),體驗者有高 達100%的滿意效果。體驗期間體驗者的肝臟指數(麩氨基酸草醋 酸轉氨基酵素及麵氨基酸焦葡萄轉氨基酵素)及腎臟指數(肌酸 酐),都沒有上升,甚至還下降,證實專利配方安全不會造成 肝、腎的負擔。當體驗者不繼續服用專利配方(超過一個月),就 可以看到體驗者的血糖及血脂(除了三酸甘油酯)都有回升現 象,證實所降的血糖、血酯為專利配方的效果。 專利複方vs血糖變化的=23)Control 0% 100% 2003⁄4 300% 400% 5003⁄4 600?ό FUf / RUi Figure 1 The above formula is further tested in vivo for blood lipids, blood sugar and fatty liver to further confirm its efficacy 201100088 _ blood lipid blood glucose animal experiment: The C57BL/6 strain mice purchased by the Chengdu Animal Center were induced by high-fat diet to cause hyperglycemia and hyperlipidemia. After we designed the mice, we found that the mice were fed after 3 weeks. It has the effect of lowering blood sugar (14.6 %) and triglyceride (21.8%), while in the sixth week, the effect of lowering cholesterol (12.4%) can be seen. _ Blood lipids and blood sugar human experience: In the blood sugar experience part, after one month of taking, the average blood glucose level decreased from 99.1 mg / dl to 94.3 mg / dl (decreased 5%). In the blood lipid experience part, after one month of testing, the average cholesterol value of all experiencers decreased from 233 mg/dl to 207 mg/dl (a decrease of 11.1%); while the average value of triglycerides was 221 mg/dl. Dropped to I62mg/dl (a decrease of 26.7%), the experience has a 100% satisfaction. During the experience, the experiencer's liver index (breast amino acid acetic acid transaminase and amino acid pyrogal aminotransferase) and kidney index (creatinine) did not rise or even decreased, confirming that the patented formula would not cause liver and kidney. The burden. When the experiencer does not continue to take the patented formula (more than one month), it can be seen that the blood sugar and blood lipids (except triglycerides) of the experience have rebounded, confirming that the blood sugar and blood esters are the result of the patented formula. Patent compound vs blood sugar change = 23)

7 201100088 專利複方VS三酸甘油脂變化(N=21) =3 "bJl s 400 350 300 250 200 150 100 50 0 〇〇1 η Ί 1^1 Q 17J 0_ 1 使用前 酬月 2個月 專利複方VS膽固醇變化(N=23)7 201100088 Patent compound VS triglyceride change (N=21) =3 "bJl s 400 350 300 250 200 150 100 50 0 〇〇1 η Ί 1^1 Q 17J 0_ 1 2 month patent before use Compound VS cholesterol change (N=23)

使用前 1個月 2個月 肝臟指標 80 60 40 20 0 3001 month 2 months before use Liver index 80 60 40 20 0 300

GOT '1 3:.8 3;.2GOT '1 3:.8 3;.2

Ξ食用前 1個月 □ 2個月1 month before consumption □ 2 months

GPTGPT

8 201100088 脂肪肝動物實驗··以成大動物中心所購買的C57BL/6品系老鼠, 經過高脂肪及高果糖飼料誘發,並於飲水中加入酒精,使老鼠 產生脂肪肝的症狀,經過我們設計的配方餵食老鼠,可以發現 老鼠經過2個月餵食後,可以調降肝指數(麩氨基酸焦葡萄轉 風基酵素),有服用專利配方老鼠的麩氨基酸焦葡萄轉氨基酵 素指數由50 U/L降到36 U/L,沒有服用專利配方控制組的麵氨 基酉文焦葡萄轉氨基酵素指數由51 υ/L上升到55 U/L。另外也犧 牲老取,由老鼠的肝臟可以發現,有服用配方老鼠的肝臟三酸 甘油@旨含量平均為23 mg,沒有服用配方的控制組平均為28mg, 且有顯著差異,而老鼠腹部以及皮下的跡,服料利配方明 顯比没有服用的低,因此此專利配方具有減少脂肪堆積之效。8 201100088 Fatty Liver Animal Experiment··C57BL/6 strain mice purchased by Chengda Animal Center, induced by high fat and high fructose feed, and added alcohol to drinking water to make the symptoms of fatty liver in mice. Formulated to feed the mice, you can find that after 2 months of feeding, the rats can reduce the liver index (brome amino acid Jiao grape to wind-based enzyme), and the patented formula of the bran amino acid Jiao grape transaminase index from 50 U / L At 36 U/L, the transaminase index of the amino-based sorghum grape without the patented formula control group increased from 51 υ/L to 55 U/L. In addition, it also sacrificed the old take, which can be found in the liver of mice. The average level of liver triglyceride in the formula rats is 23 mg, and the control group without the formula is 28 mg on average, and there are significant differences, while the mouse abdomen and subcutaneous The traceability of the formula is significantly lower than that of the non-drinking formula, so this patented formula has the effect of reducing fat accumulation.

201100088 脂肪分布比例 30 r201100088 Fat distribution ratio 30 r

control □專利複方 總脂肪 月复部脂肪 皮下脂肪 fl旨肪肝人體難:此專伽方進行人體顧,三個脱可以看到 平均生化值有瓣的效果,包括錢級草醋酸轉氨基酵素(由 46 U/L調降到30 U/L),麩氨基酸焦葡萄轉氨基酵素(由必肌 調降到35肌),三酸甘油醋(由2〇4 mg/dl調降到i69吨他),總膽 固醇(由220mg/dl t周降到2〇〇mg/dl)都有明顯的改善,甚至有紐 體驗者可祕3個肋,φ超讀判_巾度脂 輕度或輕中度脂肪肝。 取两Control □ patent compound total fat month complex fat subcutaneous fat fl fat liver human body difficult: this special gamma for the human body, three off can see the average biochemical value of the effect of the flap, including the money grade grass acetic acid transaminase ( Reduced from 46 U/L to 30 U/L), bran amino acid pyropolyaminogen (from muscle to 35 muscle), triglyceride (from 2〇4 mg/dl down to i69 tons he ), total cholesterol (from 220mg / dl t weeks to 2 〇〇 mg / dl) have significant improvement, even the experience of the New Zealand can be secret 3 ribs, φ super reading _ towel fat or light Degree of fatty liver. Take two

GPT異常(N=12)GPT anomaly (N=12)

細前刪後 201100088 目前此專利配方不同於市面上只作用於腸胃道’抑制油脂吸收 的產品’且市面上也沒有同時訴求降血糠及降血脂以及改善脂肪肝 多效的產品’所以這個專利配方及其各素材之抽出法,是具有新穎 性及進步性、產業利用之專利要件。 【圖式簡單說明】 【主要元件符號說明】After the detailed deletion of 201100088, this patent formula is different from the product that only acts on the gastrointestinal tract 'inhibiting oil absorption' on the market, and there is no product on the market that simultaneously appeals to lowering blood stasis and lowering blood fat and improving the efficacy of fatty liver. The formula and the extraction method of each material are patents with novelty, progress and industrial utilization. [Simple diagram description] [Main component symbol description]

Claims (1)

201100088 七、申請專利範圍: 1. 一種具有調降血糖血脂以及脂肪肝的多效複方食品組合,其特徵在 於組合苦瓜、綠藻、甘草、大豆蛋白粉之複方食品。 2. —種具有調降血糖血脂以及脂肪肝的多效複方食品組合之各素材抽 出物之抽取方法。 3. 依申請專利範圍第1項所述之多效複方食品組合物,其添加比例為: 苦瓜20〜40%、甘草1%〜10%、綠藻15%〜3〇%、大豆蛋白粉2(μ4〇0/〇。 4. 依申請專利範圍第2項所述之各素材抽出物之抽取方法分別為: 甲、古瓜抽出物:100克新鮮苦瓜先以榨汁機搾取苦瓜汁液,餘 渣再以100〜200 ml 90%以上的酒精浸泡6至8個小時後,過 去除殘渣,把苦瓜汁液和酒精抽提物混合進行冷凍乾燥,製 乙 丙 草出物:100克甘草經過粉碎後,加入500〜1000ml體積 =純士以6(H〇〇rpm振盪室溫浸泡1〇小時以上,除去甘草殘渣後 月液冷凍乾燥成粉末,此一粉末再以50~100ral曱醇浸泡20 小時,將醇溶的部份再乾燥成粉末而成。 出物U00克破壁綠藻粉,以500~1000ml l〇〇t:沸水 分鐘’將此水溶液以1Gmm—5 mm以分子篩過濾、, 除去卩伤’水溶液部分進行濃縮與乾燥喷粉而成。 η视粉:100克脫油的豆柏’以300〜500ml的水,加入 分解酵素endopeptidase (E.C. 3· 4. 24. 28 ),於 Ο loooo ? J Hi專帛1項所叙乡魏方食1^組合物,其產品型態包 枯·膠囊錠劑、粉類與口服液四種型態。 12 201100088 四、指定代表圖: (一) 本案指定代表圖為:第(無)圖。 (二) 本代表圖之元件符號簡單說明: 無201100088 VII. Scope of application for patents: 1. A multi-effect combination of foods with blood sugar lowering and fatty liver, which is characterized by a combination of bitter gourd, green algae, licorice and soy protein powder. 2. A method for extracting each material extract of a multi-effect compound food combination having blood sugar lowering blood fat and fatty liver. 3. According to the multi-effect compound food composition described in Item 1 of the patent application, the addition ratio is: 20~40% of bitter gourd, 1%~10% of licorice, 15%~3〇% of green algae, soy protein powder 2 (μ4〇0/〇. 4. The method for extracting the materials according to item 2 of the patent application scope is as follows: A, Gourd extract: 100 g of fresh bitter gourd, first extract the bitter gourd juice with a juicer, and After the slag is immersed in 100~200 ml of 90% alcohol for 6 to 8 hours, the residue is removed, and the bitter gourd juice and the alcohol extract are mixed and freeze-dried to produce ethyl acetoacetate: 100 g of licorice is crushed. Add 500~1000ml volume=pure to 6(H〇〇rpm, shake at room temperature for more than 1 hour, remove the licorice residue, freeze the liquid into a powder, and then soak the powder for 50 hours with 50~100ral sterol. The alcohol-soluble fraction is further dried into a powder. The U00 gram broken green algae powder is discharged at 500-1000 ml l〇〇t: boiling water for a minute. The aqueous solution is filtered at a molecular sieve of 1 Gmm-5 mm to remove hydrazine. The wound 'aqueous solution part is concentrated and dried to spray powder. η visual powder: 100 grams of oil removal Bean cypress '300~500ml of water, added decomposing enzyme endopeptidase (EC 3· 4. 24. 28), Yu loo loooo ? J Hi specializes in 1 Xuxiang Xiangfang food 1^ composition, its product type There are four types of capsules, capsules, powders and oral liquids. 12 201100088 IV. Designation of representative drawings: (1) The representative representative of the case is: (No). (2) Symbols of the representative figure Brief description: None 五、本案若有化學式時,請揭示最能顯示發明特徵的化學式:5. If there is a chemical formula in this case, please disclose the chemical formula that best shows the characteristics of the invention:
TW98121165A 2009-06-24 2009-06-24 Extraction methods and compositions to ameliorate hyperlipidemia, hyperglycermia and fatty liver TWI387460B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
TW98121165A TWI387460B (en) 2009-06-24 2009-06-24 Extraction methods and compositions to ameliorate hyperlipidemia, hyperglycermia and fatty liver

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TW98121165A TWI387460B (en) 2009-06-24 2009-06-24 Extraction methods and compositions to ameliorate hyperlipidemia, hyperglycermia and fatty liver

Publications (2)

Publication Number Publication Date
TW201100088A true TW201100088A (en) 2011-01-01
TWI387460B TWI387460B (en) 2013-03-01

Family

ID=44836453

Family Applications (1)

Application Number Title Priority Date Filing Date
TW98121165A TWI387460B (en) 2009-06-24 2009-06-24 Extraction methods and compositions to ameliorate hyperlipidemia, hyperglycermia and fatty liver

Country Status (1)

Country Link
TW (1) TWI387460B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102697060A (en) * 2012-05-23 2012-10-03 广东省农业科学院农业生物技术研究所 Bitter-gourd nutritious food with auxiliary hypoglycemic effect and preparation method thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI627959B (en) 2014-10-02 2018-07-01 景岳生物科技股份有限公司 Use of lactobacillus reuteri gmnl-263 for manufacturing composition for increasing expression of ldl-r and cyp7a1 in liver in high-fat diet individual

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102697060A (en) * 2012-05-23 2012-10-03 广东省农业科学院农业生物技术研究所 Bitter-gourd nutritious food with auxiliary hypoglycemic effect and preparation method thereof
CN102697060B (en) * 2012-05-23 2014-04-09 广东省农业科学院农业生物技术研究所 Bitter-gourd nutritious food with auxiliary hypoglycemic effect and preparation method thereof

Also Published As

Publication number Publication date
TWI387460B (en) 2013-03-01

Similar Documents

Publication Publication Date Title
US7976880B2 (en) Pregnane glycoside compositions and Caralluma extract products and uses thereof
JP4229942B2 (en) Fat metabolism promoter or anti-diabetic agent
CN101043896A (en) Carbohydrase inhibitors derived from fagaceous plants and use thereof
JP2006191830A (en) Food for suppressing fat accumulation
FR2867076A1 (en) FOOD SUPPLEMENTS AND PHARMACEUTICAL PRODUCTS
CN1870986A (en) Insulin secretion potentiator
JP2006131578A (en) Extract obtained from plant body of lotus, method for producing the extract and obesity inhibitor
TW201100088A (en) Extraction methods and compositions to improve hyperlipidemia, hyperglycermia and fatty liver
JP2011148748A (en) Adiponectin secretion-promoting composition
JP6133471B2 (en) Xanthine oxidase inhibitor
WO2007100103A1 (en) Ameliorating agent for metabolic syndrome
CN1751693A (en) Application of astragaloside in medicine for treating or preventing insulin resistance
CN101057674A (en) Composition for preventing and curing diabetes
JP2007269631A (en) Agent for suppressing accumulation of neutral fat
JP3628999B2 (en) Anonymous tea and its manufacturing method
Rebollo‐Hernanz et al. Cocoa shell: source of novel bioactive ingredients for the prevention of cardiometabolic diseases
JP5794678B2 (en) Glucagon-like peptide-1 secretion promoter
WO2010116866A1 (en) Agent for ameliorating or preventing metabolic syndrome
JP2009029786A (en) Pancreatic lipase inhibitor, its production method and therapeutic method
CN105831675A (en) Eyesight-improving and heart-clearing agrocybe cylindracea-walnut kernel and preparation method thereof
JP2009029748A (en) Colon cancer suppressing agent using chinese yam
JP2004161644A (en) Pancreatic lipase inhibitor and food product containing the inhibitor
JP2009235068A (en) Ppar activator
JP7026899B2 (en) Fatty liver inhibitor
JPH0288525A (en) Medicine and ingesta for remedy and prevention of obesity